Vizen Life Sciences Pvt Ltd’s Post

Don't miss the EMA/EORTC workshop 👉 How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? 📅 29 February https://europa.eu/!TVfryM   How can you take part? ✍ In-person registration open until 15 January 💻 Online registration open until 16 February   The event will explore the importance of patient-reported data in shaping regulatory decisions on cancer treatments, featuring expert speakers and an interactive discussion with industry, academia, regulatory agencies, health technology assessment bodies, healthcare professionals and patients.   #cancerawareness #treatcancer #research

An important discussion to add to your February calendar 🗓️ #cancer #stakeholder #engagement

Don't forget to register for the EMA/EORTC workshop 👉 How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions? 📅 29 February 🔗 https://europa.eu/!TVfryM 💻 Online registration open until 16 February   The event will explore the importance of patient-reported data in shaping regulatory decisions on cancer treatments, featuring expert speakers and an interactive discussion with industry, academia, regulatory agencies, health technology assessment bodies, healthcare professionals and patients.   #cancerawareness #treatcancer #research #worldcancerday

Another case study demonstrating the potential of German claims data! 📊 In this study, we replicated the CHAARTED trial, comparing treatment outcomes in metastatic hormone-sensitive prostate cancer. By using real-world data and propensity score matching, we achieved results closely matching those of the original trial. This highlights the power of using German claims for informed healthcare decisions. Feel free to reach out to find out more on how we can help you with your research!

#WAOJournal: Exploring #biomarkers for #chronic #rhinosinusitis in adult #asthma patients within real-world healthcare settings is crucial for advancing clinical research. Identifying these biomarkers can lead to improved diagnostics, personalized treatment plans, and better patient outcomes. By delving into biological indicators associated with both conditions, healthcare professionals can enhance their understanding of the underlying mechanisms and potential correlations. This research endeavor aims to bridge gaps in current knowledge and provide valuable insights for more targeted interventions. #MedicalResearch #HealthcareInnovation https://buff.ly/3uHCUXl

🚀 The shift toward #PrecisionMedicine is transforming #healthcare, empowering providers, payers, and life sciences companies to deliver personalized, effective, and safer treatments. But… how? 🔍 By leveraging healthcare claims data, precision medicine reduces educated guesses, enhances patient outcomes, and supports clinicians in making informed decisions. Key benefits include: ✅ Tailored treatments based on genetic makeup ✅ Reduction in adverse drug events and toxicities ✅ Enhanced disease diagnosis accuracy ✅ Empowered patient control over disease and treatment We've developed a unique classification system, mapping lab testing codes from Quest Diagnostics and LabCorp to CPT4 codes, helping clinicians make appropriate treatment decisions for conditions like non-small cell lung cancer (NSCLC). Check the comments below to learn how we use precision medicine to work with life sciences, plans and providers. 

The value of #RWD for informing better trial designs, supporting regulatory decisions, and improving patient diversity is critical as we continue to close the gap between care and research. Neal Meropol, Flatiron's Head of Research Oncology, was recently interviewed on The Bio Report with Daniel Levine to explain how #realworlddata from the EHR is transforming cancer #clinicaltrials and drug development. Tune in to learn how Flatiron Health is harnessing the power of RWD to reshape the landscape of oncology research and accelerate the development of new treatments. ▶️ https://lnkd.in/g7YvHNK3

Many thanks to Daniel Levine for a great conversation on The Bio Report podcast about the many ways that #realworlddata can support evidence generation to benefit cancer patients, in particular recent approaches to enhancing trial representativeness by applying RWD to study design, and reducing patient and site burden by streamlining data collection needs. The closer we can integrate #clinicaltrials into routine care, the more likely that study results will be generalizable to ALL cancer patients.

At TREAT-NMD, our commitment to advancing the diagnosis, treatment, and care for those affected by neuromuscular diseases is unwavering. We are thrilled to unveil our 2022 – 2023 impact report, showcasing the strides we've made in pursuit of this critical mission through: ✅ Informing the Community: Providing vital updates on research, trials, and best practice. ✅ Connecting Stakeholders: Connecting leaders, patient organisations, and industry partners to drive innovation. ✅ Advancing Therapeutics: Accelerating ground-breaking treatments and de-risking trials. This progress reflects our team's dedication and global collaboration. Explore our Impact Report > https://lnkd.in/erTbTSdp to learn more about our journey. Together, we're transforming lives. #TREATNMD #NeuromuscularDiseases #ImpactReport #TransformingLives

The National institute for Clinical Excellence (NICE) in the #UK has indicated in its 2021-2026 Transformation Plan that the use of Real World Evidence as outlined in the framework document ( https://lnkd.in/eBwEKwV2 ) can improve our understanding of health and social care and the effects of interventions on patient outcomes. Contact DaSH Global on [email protected] to discover how we are harnessing the latest technology to drive change in the treatment of Lung Cancer and Mesothelioma. DaSH Global: Improving Outcomes. Transforming Lives. Bridging The Gap Between People, Health & Pharma #NICE #TransformationPlan #RWE #SocialCare #PatientOutcomes #Healthcare #NHS #LungCancer #Mesothelioma #Pharma #MarketAccess Vivienne Law Andrew Turner Lee Wemyss